Search

Your search keyword '"Rangaraj, Ajay"' showing total 8 results
Start Over Author "Rangaraj, Ajay" Publisher elsevier ltd
8 results on '"Rangaraj, Ajay"'

3. What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies

Author

Burger, David, Bekker, Adrie, Cressey, Tim, Hirt, Deborah, Lutsar, Irja, Mcilleron, Helen, Standing, Joe, Van den Anker, John, Svensson, Elin, Abrams, Elaine, Amuge, Pauline, Archary, Mo, Belew, Yodit, Best, Brookie, Bygrave, Helen, Capparelli, Edmund, Casas, Esther, Clarke, Diana, Clayden, Polly, Colbers, Angela, Dangarembizi, Mutsa, De Lisa, Roberto, Denti, Paolo, Domanico, Paul, Essajee, Shaffiq, Frigati, Lisa, Giaquinto, Carlo, Gibb, Diana, Hackett, Stephanie, Hazra, Rohan, Lallemant, Marc, Lewis, Linda, Lockman, Shahin, Mahaka, Imelda, McFarland, Betsy, Meere, Cathal, Mir, Fatima, Mirochnick, Mark, Mofenson, Lynne, Mukui, Irene, Mushavi, Angela, Musiime, Victor, Namusoke-Magongo, Eleanor, Obimbo, Elisabeth, Ojoo, Mary Atieno, Parades, Roger, Perez-Casas, Carmen, Piccolis, Manuele, Pinto, Jorge, Puthanakit, Thanyawee, Rakhmanina, Natella, Reinisch, Annette, Rojo, Pablo, Rouzier, Vanessa, Ruel, Ted, Sam-Agudu, Nadia, Siberry, George, Simione, Teresa, Simon, Katie, Singh, Vindi, Solares, Manjari, Sugandhi, Nandita, Sylla, Mariam, Thior, Ibou, Turkova, Anna, Vicari, Marissa, Walsh, Jenny, Watkins, Melynda, Wolf, Hilary, Hafiz, Asma, Penazzato, Martina, Rangaraj, Ajay, Doherty, Meg, Vitoria, Marco, Jacobs, Tom G, Schouwenburg, Stef, Archary, Moherndran, Ruel, Theodore D, van den Anker, John, Burger, David M, Cressey, Tim R, Abrams, Elaine J, and Lyall, Hermione

Published
2022
Full Text
View/download PDF

4. Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa

Author

Revill, Paul, Rangaraj, Ajay, Makochekanwa, Albert, Mpofu, Amon, Ciaranello, Andrea L., Jahn, Andreas, Gonani, Andrew, Phillips, Andrew N., Bershteyn, Anna, Zwizwai, Benson, Nichols, Brooke E., Pretorius, Carel, Kerr, Cliff C., Carlson, Cindy, Ten Brink, Debra, Mudimu, Edinah, Kataika, Edward, Lamontagne, Erik, Terris-Prestholt, Fern, Cowan, Frances M., Manthalu, Gerald, Oberth, Gemma, Mayer-Rath, Gesine, Semini, Iris, Taramusi, Isaac, Eaton, Jeffrey W., Zhao, Jinjou, Stover, John, Izazola-Licea, Jose A, Kripke, Katherine, Johnson, Leigh, Bansi-Matharu, Loveleen, Gorgons, Marelize, Morrison, Michelle, Chagoma, Newton, Mugurungi, Owen, Stuart, Robyn M., Martin-Hughes, Rowan, Nyirenda, Rose, Barnabas, Ruanne V., Mohan, Sakshi, Kelly, Sherrie L., Sibandze, Sibusiso, Walker, Simon, Banda, Stephen, Braithwaite, R. Scott, Chidarikire, Thato, Hallett, Timothy B., Kalua, Thoko, Apollo, Tsitsi, and Cambiano, Valentina

Published
2022
Full Text
View/download PDF

7. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis

Author

Kanters, Steve, Vitoria, Marco, Zoratti, Michael, Doherty, Meg, Penazzato, Martina, Rangaraj, Ajay, Ford, Nathan, Thorlund, Kristian, Anis, Prof. Aslam H., Karim, Mohammad Ehsanul, Mofenson, Lynne, Zash, Rebecca, Calmy, Alexandra, Kredo, Tamara, and Bansback, Nick

Published
2020
Full Text
View/download PDF

8. Paving the way for affordable and equitable liposomal amphotericin B access worldwide.

Author

Lee JSF, Cohen RM, Khan RA, Burry J, Casas EC, Chung HY, Costa LH, Ford N, Galvao DLN, Giron N, Jarvis JN, Mondal M, Odionyi JJ, Casas CP, Rangaraj A, Rode J, Ruffell C, Sued O, and Ribeiro I

Subjects
Humans, Health Services Accessibility, Global Health, Developing Countries, Drugs, Generic economics, Drugs, Generic supply & distribution, Amphotericin B economics, Antifungal Agents economics, Antifungal Agents supply & distribution, Antifungal Agents therapeutic use
Abstract

Amphotericin B has long been crucial for treating many serious infectious diseases, such as invasive fungal infections and visceral leishmaniasis, particularly for patients who are immunocompromised, including those with advanced HIV infection. The conventional amphotericin B deoxycholate formulation has largely been replaced in high-income countries with liposomal amphotericin B (LAmB), which has many advantages, including lower rates of adverse events, such as nephrotoxicity and anaemia. Despite an evident need for LAmB in low-income and middle-income countries, where mortality from invasive fungal infections is still substantial, many low-income and middle-income countries still often use the amphotericin B deoxycholate formulation because of a small number of generic formulations and the high price of the originator LAmB. The pricing of LAmB is also highly variable between countries. Overcoming supply barriers through the availability of additional quality-assured, generic formulations of LAmB at accessible prices would substantially facilitate equitable access and have a substantial effect on mortality attributable to deadly fungal infections., Competing Interests: Declaration of interests JNJ reports funding from National Institute for Health and Care Research and US Centers for Disease Control and Prevention. All other authors declare no competing interests., (Copyright © 2024 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY NC ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results